Disease Detail

ID DOID:1115
Name sarcoma
Definition A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.
Source DiseaseOntology.org
Alt Ids DOID:3936
Path disease disease of cellular proliferation cancer cell type cancer sarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Pazopanib sarcoma not applicable detail...
TP53 wild-type MK-1775 + Gemcitabine sarcoma sensitive detail...
TP53 P72R Doxorubicin + Ifosfamide sarcoma sensitive detail...
Unknown unknown RG7112 sarcoma not applicable detail...
MET act mut BMS-777607 sarcoma sensitive detail...
Unknown unknown Alvocidib + Aldoxorubicin sarcoma not applicable detail...
TP53 mutant Pazopanib + Vorinostat sarcoma sensitive detail...
Unknown unknown Abexinostat + Doxorubicin sarcoma not applicable detail...
Unknown unknown Conatumumab + Ganitumab sarcoma not applicable detail...
Unknown unknown Ganitumab sarcoma not applicable detail...
Unknown unknown Lenvatinib sarcoma not applicable detail...
Unknown unknown Dasatinib sarcoma not applicable detail...
CTNNB1 S45F Imatinib sarcoma sensitive detail...
CTNNB1 act mut Imatinib sarcoma sensitive detail...
CTNNB1 T41A Imatinib sarcoma sensitive detail...
Unknown unknown Panobinostat + Epirubicin sarcoma not applicable detail...
TP53 mutant Pazopanib sarcoma sensitive detail...
PTEN loss YU238259 sarcoma sensitive detail...
SMO S387N Vismodegib sarcoma decreased response detail...
SMO D384N Vismodegib sarcoma decreased response detail...
SMO N219D Vismodegib sarcoma decreased response detail...
Unknown unknown Doxorubicin + Olaratumab sarcoma not applicable detail...
Unknown unknown Doxorubicin + Trabectedin sarcoma no benefit detail...
NRAS mutant Trametinib sarcoma resistant detail...
Unknown unknown Carotuximab + Pazopanib sarcoma not applicable detail...
Unknown unknown Anlotinib sarcoma not applicable detail...
Unknown unknown Alisertib sarcoma not applicable detail...
IDH1 R132C Olaparib sarcoma sensitive detail...
IDH1 R132C AGI-5198 + Talazoparib sarcoma decreased response detail...
IDH1 R132C AGI-5198 + Olaparib sarcoma decreased response detail...
Unknown unknown Regorafenib sarcoma not applicable detail...
Unknown unknown Pazopanib + Trametinib sarcoma no benefit detail...
Unknown unknown Pembrolizumab sarcoma not applicable detail...
ERBB2 positive HER2 CAR-T cells sarcoma predicted - sensitive detail...
TP53 mutant GDC-0575 + Gemcitabine sarcoma predicted - sensitive detail...
Unknown unknown Olaparib + Trabectedin sarcoma not applicable detail...
Unknown unknown Doxorubicin + Nilotinib sarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Recruiting
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed
NCT01010958 Phase I Valproic acid Adjuvant Valproate for High Grade Sarcomas Terminated
NCT01106872 Phase Ib/II Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Completed
NCT01154452 Phase Ib/II Vismodegib Vismodegib + RO4929097 RO4929097 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed
NCT01189643 Phase I Temozolomide + Irinotecan + Bevacizumab Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor Active, not recruiting
NCT01294670 Phase Ib/II Vorinostat + Etoposide Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Active, not recruiting
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Active, not recruiting
NCT01418001 Phase Ib/II Gemcitabine + Docetaxel + Pazopanib Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed
NCT01446809 Phase I Doxorubicin + Ifosfamide Pazopanib + Doxorubicin + Ifosfamide Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Unknown status
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed
NCT01518413 Phase I Sorafenib + Irinotecan Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01532687 Phase II Gemcitabine Gemcitabine + Pazopanib Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting
NCT01593748 Phase II Gemcitabine + Docetaxel Gemcitabine + Pazopanib A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Active, not recruiting
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01643278 Phase I Dasatinib + Ipilimumab Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic Completed
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01719302 Phase Ib/II Gemcitabine + Docetaxel + Pazopanib Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma Completed
NCT01719744 ENMD-2076 Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma Completed
NCT01746238 Phase I Doxorubicin + Bevacizumab Bevacizumab/Doxorubicin/Radiation for Sarcoma Active, not recruiting
NCT01755195 Phase II Cabozantinib Cabozantinib for Adults With Advanced Soft Tissue Sarcoma Active, not recruiting
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Recruiting
NCT01946529 Phase II Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Active, not recruiting
NCT01975519 Phase I Carotuximab + Pazopanib A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Active, not recruiting
NCT02008877 Phase Ib/II Ganetespib + Sirolimus A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST Completed
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02049905 Phase III Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Gemcitabine + Docetaxel Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed
NCT02050919 Phase II Epirubicin + Ifosfamide + Sorafenib Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Active, not recruiting
NCT02066181 Phase III Sorafenib Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Active, not recruiting
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-a ATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02180698 Phase I GLA-SE TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT02180867 Phase II Pazopanib Doxorubicin + Ifosfamide Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) Active, not recruiting
NCT02192541 Phase I Ganetespib + Aflibercept Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated
NCT02267083 Phase II GPX-150 Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma Completed
NCT02300545 Phase II Pazopanib Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy Recruiting
NCT02319824 Phase I NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy Completed
NCT02323191 Phase I Atezolizumab LY3022855 A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors Active, not recruiting
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status
NCT02357810 Phase II Topotecan + Pazopanib Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting
NCT02423863 Phase II poly ICLC In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol Recruiting
NCT02432963 Phase I MVAp53 Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting
NCT02451943 Phase III Olaratumab Doxorubicin A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02500797 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma Suspended
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02558140 Phase I RG7386 A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors Completed
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting
NCT02576431 Phase II Larotrectinib Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Recruiting
NCT02584309 Phase II dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT02584647 Phase Ib/II Pexidartinib + Sirolimus Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) Recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Active, not recruiting
NCT02636725 Phase II Axitinib + Pembrolizumab Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Active, not recruiting
NCT02639546 Phase I Cobimetinib iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors Recruiting
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Recruiting
NCT02643303 Phase Ib/II MEDI4736 + poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02646319 Phase II Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting
NCT02659020 Phase Ib/II Olaratumab Gemcitabine + Docetaxel A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Recruiting
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02783599 Phase I Doxorubicin + Olaratumab A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma Active, not recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3039478 + LY3023414 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02795819 Phase I AR-42 + Pazopanib Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Active, not recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting
NCT02839694 Phase I Decitabine + Tetrahydrouridine Decitabine + Tetrahydrouridine + Celecoxib Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Recruiting
NCT02888665 Phase Ib/II Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery Suspended
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Recruiting
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting
NCT03042819 Phase I Selinexor + Doxorubicin Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas Recruiting
NCT03056001 Phase II Doxorubicin + Pembrolizumab Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma Recruiting
NCT03056599 Gemcitabine Interferon alfa-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Recruiting
NCT03069378 Phase II Pembrolizumab + talimogene laherparepvec A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Recruiting
NCT03126591 Phase I Olaratumab + Pembrolizumab A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT03138161 Phase Ib/II trabectedin + Ipilimumab + Nivolumab Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Recruiting
NCT03139331 Phase I Pazopanib + Irinotecan + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Recruiting
NCT03149120 Phase II Nivolumab Nivolumab + Pazopanib Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Withdrawn
NCT03168061 Phase Ib/II NC-6300 Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma Recruiting
NCT03217266 Phase I AMG 232 MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma Recruiting
NCT03283696 Phase I Doxorubicin + Ifosfamide + Mesna + Olaratumab A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting
NCT03307616 Phase II Nivolumab + Ipilimumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting
NCT03338959 Phase Ib/II Pembrolizumab Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Suspended
NCT03365791 Phase II LAG525 PDR001 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03397186 Phase II Trabectedin Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Suspended
NCT03414229 Phase II Epacadostat + Pembrolizumab A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Recruiting
NCT03449108 Phase II Cyclophosphamide + Fludarabine + IL-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03463408 Phase I Nivolumab + Ipilimumab Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma Recruiting
NCT03465592 Phase Ib/II Nivolumab Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma Recruiting
NCT03474640 Phase I JS001 Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Recruiting
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Not yet recruiting
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03660930 Phase Ib/II Nab-Rapamycin + Pazopanib Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Patients With Nonadipocytic Soft Tissue Sarcomas Not yet recruiting
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Not yet recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting
NCT03719430 Phase II APX005M + Doxorubicin + Olaratumab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Not yet recruiting